VCYT - Veracyte GAAP EPS of -$0.11 beats by $0.03 revenue of $82.42M beats by $6.67M
2023-05-04 16:46:35 ET
- Veracyte press release ( NASDAQ: VCYT ): Q1 GAAP EPS of -$0.11 beats by $0.03 .
- Revenue of $82.42M (+21.6% Y/Y) beats by $6.67M .
- Testing revenue was $72.4 million, an increase of 29% compared to $56.0 million in the first quarter of 2022 driven primarily by the strong performance of our Decipher Prostate and Afirma tests. Product revenue was $3.9 million, an increase of 31% compared to $3.0 million in the first quarter of 2022. Biopharmaceutical and other revenue was $6.1 million, a decrease of 30% compared to $8.8 million in the first quarter of 2022.
- The company is raising full-year 2023 total revenue guidance to $330 million to $340 million vs $330.51M consensus, representing year-over-year growth of 11% to 15%, and an improvement compared to prior guidance of $325 million to $335 million.
For further details see:
Veracyte GAAP EPS of -$0.11 beats by $0.03, revenue of $82.42M beats by $6.67M